Retatrutide vs tirzepatide: what can we compare?
Both drugs affect hunger and blood sugar, but only tirzepatide is approved. Separate Phase 2 studies can’t settle which works better.
How are retatrutide and tirzepatide different?
Tirzepatide and retatrutide are related, but they aren’t the same drug. Tirzepatide is approved for type 2 diabetes and obesity.
Tirzepatide copies two hormones, which are body messages carried in the blood. Retatrutide copies those two and a third that may raise the calories your body uses while resting, but retatrutide isn’t approved for your care.
The retatrutide vs tirzepatide question is whether the third action adds help or harm. Separate Phase 2 results from the middle-sized round hint at more weight loss with retatrutide, but Phase 2 can’t give a fair direct answer.
A study in Eli Lilly’s final test round will compare both drugs under the same rules. It hadn’t reported by mid-2026.
What may retatrutide’s third hormone action add?
Both drugs copy a body hormone that cuts hunger and makes food remain in the stomach for more time. The hormone also tells the pancreas, an organ behind the stomach, to release insulin so sugar can move from blood into cells.
Retatrutide adds the action of glucagon, another hormone made by the pancreas. Glucagon can tell the liver to draw on stored fat and may raise the calories used while the body rests.
Eating less and burning more stored fat could lower weight further. Separate Phase 2 results fit that idea, but they can’t prove the third action caused the difference.
A faster resting pulse is the main added concern [8]. In a dish, retatrutide also made pieces of human upper-heart tissue squeeze harder; no human test has shown whether that is dangerous or tied to the faster pulse [8].
What can separate Phase 2 studies tell you?
The two Phase 2 results came from different people, time spans, and study plans. You can’t use them as a fair direct test.
Retatrutide’s Phase 2 study found 24.2% average loss in its 48-week test [1]. Tirzepatide reached about 20% at 52 weeks in 1 large Phase 3 study; that number did not come from Phase 2.
The retatrutide Phase 2 result and later tirzepatide result are about 4 percentage points apart, but they came from different stages and people. The gap can’t show which drug works better.
In lab work, retatrutide pushed one blood-sugar action much harder than the body’s own hormone [3]. A dish test can’t show whether that stronger action helps or harms a person.
In 2026, one review ranked retatrutide highest for weight and long-term blood-sugar change [13]. Another 2026 review found lower weight, waist size, and blood sugar with two-action or three-action drugs, while stomach trouble also grew more common [14].
When will one study compare the two drugs?
As of 2026, a Phase 3 study included a tirzepatide group. ClinicalTrials.gov has the details for this large final test.
People will enter the two drug groups by chance. That helps keep the study rules alike on both sides.
Results haven’t been published. Until then, retatrutide vs tirzepatide claims must rely on separate studies that used different plans.
The separate Phase 2 numbers don’t settle the question. No published direct result proves which drug works better [12].
Why does approval matter in this comparison?
Tirzepatide is approved medicine. The FDA reviewed its large studies, doctors may prescribe it, and new harm reports keep being watched.
Retatrutide isn’t approved and remains in Phase 3. Large, long studies haven’t settled later changes in the heart, kidneys, or weight after a person stops.
These facts matter when you compare the drugs. Tirzepatide has an approval record, while retatrutide doesn’t have one yet.